Do you have cutaneous sarcoidosis? Would you be interested in hearing more about a clinical study on cutaneous sarcoidosis? If so, you may be able to participate in a research study to find out how effective and safe the study medication Brepocitinib is in patient with cutaneous sarcoidosis.

We are looking for adults ages 18-55 who are interested in using digital tools, a website, and text messages to help them make positive changes in their eating, activity, and weight.

The main purpose of the study is to determine whether the experimental study drug, AI-081, is safe and well tolerated, and whether it is effective in treating advanced cancer that cannot be removed by surgery or has spread to a different part of the body (metastasis).

Are you interested in an eye-tracking study? Participate in our study! We are giving $15/hour or 1 SONA credit (plus 0.5 extra travel credit). This study is approximately one hour long. This is a research study and not a clinical treatment study. We are researching where people look while they listen to stories and view pictures about such stories. You are eligible to participate if you are 18 years or older, a native speaker of American English, with vision good enough to see and read a computer screen, and able to attend an in-person visit in the Arnold Lab, Room 371, Davie Hall at UNC. You must not have participated in other Arnold lab studies before. If you wear glasses and use lenses as well, we request that you wear lenses for the ease of participation. Also, we request that you not wear any eye makeup during participation.

The purpose of this study is to understand how Black undergraduate students feel their involvement in extracurricular activities (ECAs) affects their academic success, personal growth, and sense of identity. It also looks at how cultural relevance plays a role in these outcomes. By gathering information through surveys and focus groups, the study aims to uncover connections between ECA participation, cultural influences, and student experiences. The findings will add to research on the experiences of Black students at predominantly white institutions (PWIs), focusing on both the positive impacts and challenges of participating in ECAs at these institutions.

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Are you planning on having an IUD placed? If you are already planning to get an IUD, this study gives the chance to receive extra pain medication during insertion. Everyone will receive standard pain medication, and 2/3 of volunteers will receive extra. We are looking to see if giving ketorolac pills 1-hour vs 2-hours before an IUD decreases pain levels. We would need 3 hours of in-person clinic time from volunteers. Compensation provided.

If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .